International Clinical Trial: A prospective study to evaluate the safety and efficacy of a new three drug combination of arsenic tri oxide , all trans retinoic acid and venetoclax in the treatment of High Risk Acute Promyelocytic Leukemia

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (CTRI/2026/09/117065) titled 'A prospective study to evaluate the safety and efficacy of a new three drug combination of arsenic tri oxide , all trans retinoic acid and venetoclax in the treatment of High Risk Acute Promyelocytic Leukemia' on Sept. 7.

Study Type: Interventional

Study Design: Single Arm Study Method of generating randomization sequence:Not Applicable Method of allocation concealment:Not Applicable Blinding and masking:Not Applicable

Primary Sponsor: Department of Clinical Hematology and Medical Oncology,PGIMER,Chandigarh

Condition: Health Condition 1: D728- Other specified disorders of whiteblood cells

Interventi...